Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Carmustine is a DNA alkylating agent.1,2 It inhibits cell growth and induces cell cycle arrest at the G2/M phase in C6 rat glioma cells when used at a concentration of 10 µM.2 In vivo, carmustine (0.3 and 6.7 mg/kg per day) reduces tumor growth in a C6 rat glioma model. Carmustine (0.5 mg/kg, i.p.) also reduces the number of amyloid-β plaques and brain levels of amyloid-β (1-40) (Aβ40), as well as increases brain levels of soluble amyloid precursor protein (sAPP) in the APP/PS1 transgenic mouse model of Alzheimer’s disease.3 Formulations containing carmustine have been used in the treatment of gliomas and glioblastomas.
WARNING This product is not for human or veterinary use.
1. Clinical comparison of the nitrosoureas. Cancer 36(4), 1258-1268 (1975).
2. In vivo enhanced antitumor activity of carmustine [N,N'-
3. Striking reduction of amyloid plaque burden in an Alzheimer’s mouse model after chronic administration of carmustine. BMC Med. 11, 81 (2013).